Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 123156833 | 12315683 | 3 | F | 20160714 | 20160428 | 20160726 | EXP | CA-PFIZER INC-2016232936 | PFIZER | 45.00 | YR | F | Y | 0.00000 | 20160726 | MD | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 123156833 | 12315683 | 1 | SS | ENBREL | ETANERCEPT | 1 | Subcutaneous | 50 MG, UNK | U | 0 | 50 | MG | |||||||
| 123156833 | 12315683 | 2 | SS | ENBREL | ETANERCEPT | 1 | Subcutaneous | 25 MG, UNK | U | 0 | 25 | MG | |||||||
| 123156833 | 12315683 | 3 | SS | ANTITHYMOCYTE IMMUNOGLOBULIN | THYMOCYTE IMMUNE GLOBULIN NOS | 1 | 6.0 MG/KG, UNK | U | 0 | 6 | MG/KG | ||||||||
| 123156833 | 12315683 | 4 | PS | RAPAMUNE | SIROLIMUS | 1 | UNK | U | 21110 | ||||||||||
| 123156833 | 12315683 | 5 | SS | DACLIZUMAB | DACLIZUMAB | 1 | UNK | U | 0 | ||||||||||
| 123156833 | 12315683 | 6 | SS | DACLIZUMAB | DACLIZUMAB | 1 | UNK | U | 0 | ||||||||||
| 123156833 | 12315683 | 7 | SS | MYCOPHENOLATE MOFETIL. | MYCOPHENOLATE MOFETIL | 1 | Oral | 1000 MG, BID | U | 0 | 1000 | MG | CAPSULE | BID | |||||
| 123156833 | 12315683 | 8 | SS | NEORAL | CYCLOSPORINE | 1 | UNK | U | 0 | ||||||||||
| 123156833 | 12315683 | 9 | SS | REMICADE | INFLIXIMAB | 1 | Intravenous (not otherwise specified) | UNK | U | 0 | POWDER FOR INFUSION | ||||||||
| 123156833 | 12315683 | 10 | SS | TACROLIMUS. | TACROLIMUS | 1 | 2.5 MG, BID | U | 0 | 2.5 | MG | BID | |||||||
| 123156833 | 12315683 | 11 | SS | TACROLIMUS. | TACROLIMUS | 1 | 3 UNK, UNK | U | 0 | 3 | MG | BID | |||||||
| 123156833 | 12315683 | 12 | SS | PROGRAF | TACROLIMUSTACROLIMUS ANHYDROUS | 1 | 2.5 MG, BID | U | 0 | 2.5 | MG | BID | |||||||
| 123156833 | 12315683 | 13 | SS | PROGRAF | TACROLIMUSTACROLIMUS ANHYDROUS | 1 | Oral | 3 UNK, UNK | U | 0 | 3 | MG | BID | ||||||
| 123156833 | 12315683 | 14 | SS | PROGRAF | TACROLIMUSTACROLIMUS ANHYDROUS | 1 | Oral | 2 MG, BID | U | 0 | 2 | MG | BID | ||||||
| 123156833 | 12315683 | 15 | SS | PROGRAF | TACROLIMUSTACROLIMUS ANHYDROUS | 1 | UNK | U | 0 |
Indications of drugs used
| no results found |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 123156833 | 12315683 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 123156833 | 12315683 | Acne | |
| 123156833 | 12315683 | Alopecia | |
| 123156833 | 12315683 | Ovarian cyst | |
| 123156833 | 12315683 | Transplant dysfunction | |
| 123156833 | 12315683 | Transplant rejection |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |